Welcome to our dedicated page for Harmony Biosciences Holdings SEC filings (Ticker: HRMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Digging through Harmony Biosciences鈥� filings means wading into pages of clinical trial tables, FDA correspondence, and royalty math. If tracking WAKIX revenue trends or matching orexin pipeline milestones to cash runway feels overwhelming, you鈥檙e not alone. Harmony Biosciences SEC filings explained simply is exactly what most investors search for鈥攁nd what Stock Titan delivers.
Our platform adds AI context to every document the moment it appears on EDGAR. The latest Harmony Biosciences quarterly earnings report 10-Q filing is paired with sentence-level summaries that highlight net product sales, R&D spend, and upcoming Phase 3 readouts. A 300-page Harmony Biosciences annual report 10-K simplified shows side panels with trend graphs, while each Harmony Biosciences 8-K material events explained note spells out why an FDA Fast Track designation or safety update matters. Need governance data? The Harmony Biosciences proxy statement executive compensation section links pay packages to regulatory milestones so you can judge incentive alignment in minutes.
Compliance watchers rely on our real-time alerts for Harmony Biosciences Form 4 insider transactions real-time; one click reveals Harmony Biosciences insider trading Form 4 transactions alongside historical charts. Questions like 鈥渦nderstanding Harmony Biosciences SEC documents with AI鈥� or 鈥淗armony Biosciences earnings report filing analysis鈥� are answered through concise dashboards that connect filings to market impact. You can even export the full log of Harmony Biosciences executive stock transactions Form 4 for pattern analysis. With comprehensive coverage, AI-powered summaries, and instant access to every form type, Stock Titan turns dense biotech disclosure into clear, actionable insight.
SharpLink Gaming (SBET) filed an 8-K on 5 Aug 2025 detailing recent treasury and financing actions.
- From 28 Jul鈥�3 Aug 2025 the company purchased 83,561 ETH for $303.7 M, a $3,634 weighted-average cost.
- Total ETH holdings now stand at 521,939; staking has produced 929 ETH rewards since the strategy鈥檚 2 Jun 2025 launch.
- Substantially all ETH is deployed in liquid staking; management states this will trigger material impairment charges for the quarter ended 30 Jun 2025.
- Funding came from 13.6 M common shares sold 28 Jul鈥�1 Aug 2025 under the ATM facility, generating net proceeds of $264.5 M.
- A Reg FD press release (Ex. 99.1) accompanies the filing; information is furnished, not filed.
No earnings guidance was issued. The company cautions that staking activities may face evolving regulatory oversight.
Phoenix Motor Inc. (PEV) filed a Form 8-K reporting the resignation of Chief Financial Officer Michael Yung, effective 2 Aug 2025. The company states Mr. Yung left for personal reasons and had no disagreements regarding the firm鈥檚 operations or accounting practices.
CEO Denton Peng will serve as interim principal financial and accounting officer while the Board undertakes an internal and external search for a permanent replacement. No additional financial results or business updates were included.
The filing also notes that trading of Phoenix Motor鈥檚 common stock was suspended on Nasdaq on 15 Apr 2025 and shares now quote on the OTC Pink under the symbol PEVMD.
FAQ
What is the current stock price of Harmony Biosciences Holdings (HRMY)?
What is the market cap of Harmony Biosciences Holdings (HRMY)?
What is the primary focus of Harmony Biosciences Holdings, Inc.?
What is WAKIX and what does it treat?
How does the company generate revenue?
What makes Harmony Biosciences' approach unique?
How does Harmony Biosciences support its patient-centric model?
What role do strategic acquisitions play in the company鈥檚 growth?
How does Harmony Biosciences incorporate scientific expertise in its operations?
How does Harmony Biosciences maintain credibility in the biotech sector?
